NFKB1 and melanoma: Using a similar approach as with JNK inhibitors (Fig. 5), melanoma cells (A375 and Colo829) were treated with increasing concentrations of THZ531 in combination with two inhibitors of IKKβ (BI605906 and MLN120B), the canonical NF-κB activator43.